Inggerit Inggerit
RSU Santo Vincentius Kalimantan Barat

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search
Journal : Health Information : Jurnal Penelitian

Penggunaan Eculizumab sebagai Pilihan Terapi pada Pasien HUS dengan Transplantasi Ginjal Ilma Tria Nursyifa; Puspa Dewanti; Inggerit Inggerit; Johansen Johansen; Sylvia Regina
Health Information : Jurnal Penelitian Vol 15 No 2 (2023): Suplemen
Publisher : Poltekkes Kemenkes Kendari

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Background: Hemolytic Uremic Syndrome (HUS) is a form of thrombotic microangiopathy characterized by thrombocytopenia, microangiopathic hemolytic anemia and acute renal failure, occur in both children and adults. Eculizumab is a chimeric IgG2/4 monoclonal antibody that pairs with complement protein C5 and is used to treat or prevent relapse of HUS after kidney transplantation. Purpose: This article aims to determine the use of eculizumab as a therapeutic option in HUS patients with kidney transplants and explaining both the clinical effect and the method of administration. Method: Literature review from two databases, namely Google Scholar and PubMed, which were published within the last 5 years, from 2018-2023. Results: There were 11 literatures proving that eculizumab can be considered as a therapeutic option in HUS patients with kidney transplantation. Eculizumab can reduce the risk of recurrence or the emergence of HUS after kidney transplantation. Although most of the side effects of eculizumab are not serious, meningitis and death cannot be ruled out. So guidelines for the use of eculizumab are needed based on larger data to reduce the risk of infection and cost lost.